Innovent
Innovent including oncology
Innovent is a leading biotechnology company in China. It aims to produce highly complex and affordable biopharmaceutical products for patients. Since its inception, Innovent has established a product chain of 13 new drugs covering four major disease areas, including oncology, ophthalmology, autoimmune diseases and cardiovascular diseases, and has undertaken 7 National Science and Technology Projects, of which 5 products were selected for the National "Major New Drug Creation" Program and 1 product was selected for the National Key Research and Development Program. Special "Precision Medicine Research".
Haizheng pharmaceutical and Junshi biology signed a contract for commissioned production of Xinguan oral drug vv116
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Cinda biology and Baoyuan medicine announced that taretinib was included in the breakthrough therapeutic drug variety
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925